SAT2 and renal carcinoma: For instance, in renal cancer, SAT2 has been shown to enhance cisplatin sensitivity under hypoxia by degrading HIF-1α [7], suggesting a conserved tumor-suppressive mechanism that warrants further cross-cancer comparisons.